Google AI View: Analyst consensus forecasts for Capital A Berhad (KLSE: CAPITALA) do not specify a fixed 3-month target, but 12-month projections range from a low of RM0.44 to a high of RM0.76–RM0.93, with an average target around RM0.64 MYR. Upcoming earnings.

Key Drivers for Price Movement

PN17 Regularisation: Completing the structural corporate exercise and officially lifting the financial distress status.

Non-Aviation Segments: Strong performance and high utilization in maintenance, repair, and overhaul (ADE), logistics (Teleport), and digital units.

Macro Factors: Regional travel demand trends and stabilizing fuel costs.

Pharma will need to continuously show positive and strong Quarterly result & dividend to prove that the comeback is strong. This should not be difficult as it has strong Malaysian hospital customer base.

Pharma is very potential stock base on 2 important reasons:- 1.Production of human insulin contracts at its Puchong plant is scaling up. This moves the company away from being just a low-margin logistical middleman to a high-margin manufacturer. 2.Analysts estimate that Pharmaniaga could pay out 50% to 70% of its net profit as dividends. This is a major catalyst that will draw back large institutional funds.

Ya. Accumulate now. Once it start to fly, due to increasing travel business, revenue and profit of Cap A will increase.

Opportunity to accumulate more share.

Fund manager buying more.

As Capital A will capitialise on the improve air traffic and hence increase
ing revenue. Foresee a growing revenue and improving profit.

With the lower oil price at USD70/barrel, July & Aug Airasia Capacity Restoration & Expansion Plan

Full Capacity Target: AirAsia Group and AirAsia X plan to restore most of their previously reduced capacity and reach full operating capacity by the end of August 2026.

Frequency Hikes: The airline is steadily increasing flight frequencies and aircraft utilisation across its entire network of over 150 destinations

More fund manager can now invest in Pharma stock.

LTAT acquiring Pharma shows that the consolidation of stock to above RM1 works.